Table 4.
Unadjusted Model n=1254 |
Adjusted Model n=1198 |
|||
---|---|---|---|---|
Characteristic | Odds Ratio (95% CI) | P value | Odds Ratio (95% CI) | P value |
Unadjusted Model | ||||
Systolic Blood Pressure (per 5 mmHg increase) | 0.98 (0.97,0.99) | <.0001 | 0.998 (0.99, 1.01) | 0.70 |
Diastolic Blood Pressure (per 5 mmHg increase) | 1.04 (1.03, 1.05) | <.0001 | 1.001 (0.98, 1.02) | 0.92 |
Demographic Variables | ||||
Age (yrs). | --- | --- | 0.9494 (0.93, 0.96) | <.0001 |
African-American vs. White | --- | --- | 1.34 (0.91, 1.96) | 0.14 |
Hispanic vs. White | 0.70 (0.45, 1.11) | 0.13 | ||
Other vs. White | --- | --- | 1.07 (0.35, 3.23) | 0.91 |
< High school vs. College Graduate | --- | --- | 0.56 (0.33, 0.98) | 0.043 |
High School graduate/GED vs. College Graduate | --- | --- | 0.64 (0.43, 0.96) | 0.031 |
Post High School vs. College Graduate | --- | --- | 1.01 (0.73, 1.40) | 0.95 |
Lives with Others vs. Lives Alone | --- | --- | 1.57 (1.16, 2.13) | 0.004 |
Behavioral Risk Factor and Medication Use Variables | ||||
Pack-years of Smoking | --- | --- | 1.00 (0.99, 1.01) | 0.57 |
Alcohol Consumption (drinks/typical wk) | --- | --- | 1.06 (0.97, 1.20) | 0.20 |
Beta-blockers (BB) vs. no BB | --- | --- | 1.17 (0.86, 1.58) | 0.32 |
Diuretics vs. No Diuretics | --- | --- | 0.81 (0.61, 1.06) | 0.13 |
Calcium Channel Blockers vs.no Calcium Channel Blockers | --- | --- | 0.96 (0.72, 1.27) | 0.78 |
Angiotensin Receptor Blockers (ARB) vs. no ARB | --- | --- | 1.16 (0.86, 1.55) | 0.33 |
Angiotensin Converting Enzyme (ACE) Inhibitors vs. no ACE | 1.13 (0.77, 1.65) | 0.53 | ||
Any Cholesterol Medication | --- | --- | 1.00 (0.75, 1.34) | 0.98 |
Any Phosphodiesterase Type 5 Inhibitors | --- | --- | 3.70 (2.11, 6.48) | <.0001 |
Cardiometabolic and Psychosocial Variables | ||||
BMI (kg/m2) | --- | --- | 1.00 (0.98, 1.03) | 0.76 |
eGFR (mL/min/1.73 m2) | --- | --- | 1.00 (0.99, 1.01) | 0.54 |
MoCA Total Score a | --- | --- | 1.03 (0.99, 1.08) | 0.15 |
PHQ-9 Total Score b | --- | --- | 0.96 (0.93, 1.00) | 0.027 |
Number of Physical Comorbidities b | --- | --- | 0.93 (0.88, 0.99) | 0.015 |
--- variable not included in model
significant (p<0.05) Adjusted Odds Ratios and 95% Confidence Intervals presented in bold
Higher scores indicate better function
Higher scores indicate poorer function